FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031553719> ?p ?o ?g. }

• W2031553719 endingPage "52" @default.
• W2031553719 startingPage "47" @default.
• W2031553719 abstract "Lennox–Gastaut syndrome (LGS) severity varies considerably, so the potential impact of differences in baseline severity on patient outcome following treatment is clinically informative. Here, two surrogate indicators of LGS severity (baseline seizure frequency and vagus nerve stimulation [VNS] use) were used in post hoc analyses of both short- and long-term clobazam trials (Phase III OV-1012 [CONTAIN] and open-label extension [OLE] OV-1004). In CONTAIN, 217 patients comprised the modified, intention-to-treat population. Each baseline seizure-frequency quartile had ~40 patients, and baseline weekly drop-seizure frequency ranges were as follows: <10 (Quartile 1), 10–30 (Quartile 2), 32–86 (Quartile 3), and 86–1077 (Quartile 4). Mean percentage decreases in average weekly drop and total seizures were similar for all quartiles. More than 50% of patients in all 4 quartiles demonstrated ≥50% decreases in weekly drop- and total-seizure frequency. The percentage of patients achieving 100% reduction in drop seizures was 33% for clobazam-treated patients (vs. 7% for placebo) in Quartile 1. Five percent of clobazam-treated patients in Quartile 4 (most severe LGS) vs. 0% for placebo achieved 100% reduction in drop seizures. A total of 267 of 306 possible patients entered the OLE (61/68 from a Phase II study and 206/238 from Phase III CONTAIN). Each quartile had ~66 patients, and baseline weekly drop-seizure ranges were as follows: <10 (Quartile 1), 10–31 (Quartile 2), 32–110 (Quartile 3), and 111–1147 (Quartile 4). Median percentage decreases in average weekly drop and total seizures were similar between quartiles. Through 5 years of therapy, >50% of patients in all 4 quartiles demonstrated ≥50% decreases in weekly frequency for drop seizures. More than 12% of patients in Quartile 4 achieved 100% reduction in drop seizures from Month 3 through Year 5. For the VNS analyses in CONTAIN, the least-squares mean decreases in average weekly rate of drop seizures (mITT population) were 52% for VNS patients receiving clobazam vs. −22% for placebo (p < 0.01). For non-VNS patients, these percentages were 53% for clobazam and 26% for placebo (p < 0.01). Moreover, 50% and 54% of clobazam-treated patients in the VNS and non-VNS groups demonstrated ≥50% decreases in average weekly drop- and total-seizure frequencies, and 11% and 14% in the two groups achieved drop-seizure freedom, respectively. Analyses using baseline seizure frequency and VNS use as surrogates for disease severity showed that clobazam treatment of patients with less severe or severe LGS was equally efficacious." @default.
• W2031553719 created "2016-06-24" @default.
• W2031553719 creator A5003954328 @default.
• W2031553719 creator A5032129336 @default.
• W2031553719 creator A5036305713 @default.
• W2031553719 creator A5060176494 @default.
• W2031553719 creator A5073284312 @default.
• W2031553719 date "2014-12-01" @default.
• W2031553719 modified "2023-10-16" @default.
• W2031553719 title "Clobazam is efficacious for patients across the spectrum of disease severity of Lennox–Gastaut syndrome: Post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience" @default.
• W2031553719 cites W1527708909 @default.
• W2031553719 cites W1671458509 @default.
• W2031553719 cites W2020497106 @default.
• W2031553719 cites W2052410856 @default.
• W2031553719 cites W2080962580 @default.
• W2031553719 cites W2090654997 @default.
• W2031553719 cites W2110876059 @default.
• W2031553719 cites W2136555562 @default.
• W2031553719 cites W2137728866 @default.
• W2031553719 cites W2169966598 @default.
• W2031553719 doi "https://doi.org/10.1016/j.yebeh.2014.09.019" @default.
• W2031553719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25282105" @default.
• W2031553719 hasPublicationYear "2014" @default.
• W2031553719 type Work @default.
• W2031553719 sameAs 2031553719 @default.
• W2031553719 citedByCount "8" @default.
• W2031553719 countsByYear W20315537192015 @default.
• W2031553719 countsByYear W20315537192016 @default.
• W2031553719 countsByYear W20315537192017 @default.
• W2031553719 countsByYear W20315537192019 @default.
• W2031553719 countsByYear W20315537192022 @default.
• W2031553719 crossrefType "journal-article" @default.
• W2031553719 hasAuthorship W2031553719A5003954328 @default.
• W2031553719 hasAuthorship W2031553719A5032129336 @default.
• W2031553719 hasAuthorship W2031553719A5036305713 @default.
• W2031553719 hasAuthorship W2031553719A5060176494 @default.
• W2031553719 hasAuthorship W2031553719A5073284312 @default.
• W2031553719 hasConcept C118552586 @default.
• W2031553719 hasConcept C126322002 @default.
• W2031553719 hasConcept C142724271 @default.
• W2031553719 hasConcept C204787440 @default.
• W2031553719 hasConcept C27081682 @default.
• W2031553719 hasConcept C2777907850 @default.
• W2031553719 hasConcept C2778186239 @default.
• W2031553719 hasConcept C2779307984 @default.
• W2031553719 hasConcept C2908647359 @default.
• W2031553719 hasConcept C30036603 @default.
• W2031553719 hasConcept C44249647 @default.
• W2031553719 hasConcept C67761136 @default.
• W2031553719 hasConcept C68443243 @default.
• W2031553719 hasConcept C71924100 @default.
• W2031553719 hasConcept C99454951 @default.
• W2031553719 hasConceptScore W2031553719C118552586 @default.
• W2031553719 hasConceptScore W2031553719C126322002 @default.
• W2031553719 hasConceptScore W2031553719C142724271 @default.
• W2031553719 hasConceptScore W2031553719C204787440 @default.
• W2031553719 hasConceptScore W2031553719C27081682 @default.
• W2031553719 hasConceptScore W2031553719C2777907850 @default.
• W2031553719 hasConceptScore W2031553719C2778186239 @default.
• W2031553719 hasConceptScore W2031553719C2779307984 @default.
• W2031553719 hasConceptScore W2031553719C2908647359 @default.
• W2031553719 hasConceptScore W2031553719C30036603 @default.
• W2031553719 hasConceptScore W2031553719C44249647 @default.
• W2031553719 hasConceptScore W2031553719C67761136 @default.
• W2031553719 hasConceptScore W2031553719C68443243 @default.
• W2031553719 hasConceptScore W2031553719C71924100 @default.
• W2031553719 hasConceptScore W2031553719C99454951 @default.
• W2031553719 hasLocation W20315537191 @default.
• W2031553719 hasLocation W20315537192 @default.
• W2031553719 hasOpenAccess W2031553719 @default.
• W2031553719 hasPrimaryLocation W20315537191 @default.
• W2031553719 hasRelatedWork W1711742199 @default.
• W2031553719 hasRelatedWork W1783257732 @default.
• W2031553719 hasRelatedWork W1993260480 @default.
• W2031553719 hasRelatedWork W2031553719 @default.
• W2031553719 hasRelatedWork W2092231439 @default.
• W2031553719 hasRelatedWork W2151729238 @default.
• W2031553719 hasRelatedWork W2346134436 @default.
• W2031553719 hasRelatedWork W2780953930 @default.
• W2031553719 hasRelatedWork W2902013002 @default.
• W2031553719 hasRelatedWork W4318027231 @default.
• W2031553719 hasVolume "41" @default.
• W2031553719 isParatext "false" @default.
• W2031553719 isRetracted "false" @default.
• W2031553719 magId "2031553719" @default.
• W2031553719 workType "article" @default.